Quantcast

Latest Bivalirudin Stories

2014-08-11 16:28:29

Conference Call and Webcast, August 12, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J., Aug. 11, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its second quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held...

2014-07-29 16:27:56

BASKING RIDGE, N.J., July 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights....

2014-07-09 16:28:44

BASKING RIDGE, N.J., July 9, 2014 /PRNewswire/ -- Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI trial, the United States Food and Drug Administration (FDA) informed the company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the ongoing Phase 3 REGULATE-PCI trial. According to the FDA, this action was taken to formalize the...

2014-07-07 09:40:29

The Lancet A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin. The results of the HEAT-PPCI trial...

2014-04-02 20:22:41

REGULATE-PCI Opened to "All Comers" PCI Population BASKING RIDGE, N.J., April 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the...

2014-03-12 20:24:11

Conference Call and Webcast on March 13 at 8:30 a.m. EDT BASKING RIDGE, N.J., March 12, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT. David J....

2014-01-29 08:29:36

Additional Findings from RADAR Trial Published in Journal of Invasive Cardiology BASKING RIDGE, N.J., Jan. 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the publication of additional findings from its completed Phase 2b RADAR trial in the Journal of Invasive Cardiology(1 )demonstrating the safety...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related